Business Context and Reporting Period
Company: Arrowhead Research Corporation (a development-stage nanotechnology holding company).
Reporting Period: Quarterly period ended March 31, 2009 (Second Quarter of Fiscal 2009).
Business Model: The Company builds value by identifying, developing, and commercializing nanotechnology-related products through a portfolio of subsidiaries (Calando, Unidym, Tego, Agonn) and minority investments (Nanotope, Leonardo Biosystems). Operations are funded by cash on hand, government grants, and capital raises.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2009 | Six Months Ended Mar 31, 2009 | Balance Sheet (Mar 31, 2009) |
|---|---|---|---|
| Revenue | $235,650 | $937,373 | N/A |
| Net Loss | $(5,289,279) | $(13,319,747) | N/A |
| Operating Loss | $(5,216,322) | $(13,891,006) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $3,557,340 |
| Total Assets | N/A | N/A | $10,167,700 |
| Total Liabilities | N/A | N/A | $7,761,629 |
| Stockholders' Equity | N/A | N/A | $406,071 |
| Accumulated Deficit | N/A | N/A | $(98,816,214) |
Cash Flow (Six Months Ended Mar 31, 2009):
- Net cash used in operating activities: $(11,378,015)
- Net cash provided by investing activities: $722,454
- Net cash provided by financing activities: $4,119,316
Material Changes vs. Prior Period
- Revenue Decline: Revenue for the three months ended March 31, 2009, decreased to $235,650 from $724,766 in the prior year period. This was primarily due to a significant reduction in grant revenue to Unidym ($117,715 vs. $557,471) and lower CNT sales.
- Expense Reduction: Total operating expenses decreased by approximately $2.1 million in the quarter compared to the prior year, driven by headcount reductions and operational streamlining at subsidiaries Calando and Unidym.
- Cash Position: Cash and cash equivalents decreased by approximately $6.5 million over the six-month period, from $10.1 million to $3.6 million.
- Debt Increase: Long-term liabilities increased significantly due to the issuance of $2.5 million in unsecured convertible promissory notes by subsidiary Calando and capital lease obligations assumed by Unidym.
Guidance, Outlook, Risks, and Unusual Items
Management Strategy & Outlook:
Management has adopted a cash conservation strategy due to limited capital resources. The Company is scaling back operations at Calando and Unidym, terminating senior management at subsidiaries, and closing facilities (e.g., Unidym's Texas plant). The focus is on out-licensing technology, selling non-core assets, and seeking funded partnerships rather than internal product development.
Going Concern:
The filing explicitly states that the Company's operating losses and negative cash flows raise substantial doubt about its ability to continue as a going concern. The financial statements do not reflect adjustments that might result if the Company were unable to continue operations.
Key Risks & Contingencies:
- Intellectual Property: A material portion of Unidym's IP is exclusively licensed from Rice University. If Unidym fails to meet financial covenants or debts exceed assets, the license could terminate.
- Debt Obligations: Calando has $2.5 million in convertible notes due in 2010. Unidym has a capital lease obligation of ~$1.14 million secured by equipment.
- Put Options: Unidym has obligations to repurchase Series C-1 Preferred Stock from TEL Ventures (up to $2.4 million) if specific cash flow or joint development milestones are not met by June 30, 2009.
- Listing Status: The Company faces potential delisting from NASDAQ due to low stock price and low stockholders' equity.
Unusual Items:
- Recognized a $700,000 gain on the sale of its 50% equity interest in Ensysce BioSciences Inc.
- Subsequent events include the termination of the Unidym Texas lease and an agreement to transfer CNT manufacturing assets to Continental Carbon Nanotechnologies.
Investor Verification Checklist
- Cash Runway: Verify if the current cash balance of ~$3.6 million is sufficient to fund operations through the next 12 months given the burn rate and debt obligations.
- Debt Covenants: Confirm Unidym's ability to meet the Rice University license financial covenants and the cash flow requirements to avoid the TEL Ventures put option exercise.
- Subsidiary Monetization: Assess the progress of partnership or licensing discussions for Calando and Unidym, as internal development has been largely suspended.
- Equity Dilution: Review the terms of outstanding warrants and options, as further capital raises will likely result in significant dilution.
- Going Concern Status: Monitor for any announcements regarding additional financing, asset sales, or strategic alternatives to address the substantial doubt regarding the Company's ability to continue as a going concern.